DIACEUTICS PLC

Declaration of Voting Results & Voting Rights Announcements • May 19, 2020

National Storage Mechanism | Additional information

RNS Number : 3820N

Diaceutics PLC

19 May 2020

19 May 2020

Diaceutics PLC

("Diaceutics" or the "Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed. 

Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:

Resolution		For & Discretionary		Against		Withheld	Total votes cast
		Number of votes	%	Number of votes	%	Number of votes
1	Ordinary resolution to receive and consider the 2019 Financial Statements	50,023,247	100.00%	0	0.00%	0	50,023,247
2	Ordinary resolution to re-elect Julie Goonewardene as a director	49,984,878	99.92%	38,369	0.08%	0	50,023,247
3	Ordinary resolution to re-elect Charles Hindson as a director	49,969,009	100.00%	0	0.00%	54,238	49,969,009
4	Ordinary resolution to re-elect Mike Wort as a director	49,969,009	100.00%	0	0.00%	54,238	49,969,009
5	Ordinary resolution to re-elect Peter Keeling as a director	50,023,247	100.00%	0	0.00%	0	50,023,247
6	Ordinary resolution to re-elect Ryan Keeling as a director	49,984,878	99.92%	38,369	0.08%	0	50,023,247
7	Ordinary resolution to re-elect Philip White as a director	50,023,247	100.00%	0	0.00%	0	50,023,247
8	Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors	49,984,878	100.00%	0	0.00%	38,369	49,984,878
9	Ordinary resolution to authorise the directors to determine the remuneration of the auditors	50,007,378	100.00%	0	0.00%	15,869	50,007,378
10	Ordinary resolution to authorise the directors to allot shares	49,984,878	99.92%	38,369	0.08%	0	50,023,247
11	Special resolution to authorise the directors to disapply pre-emption rights	49,983,480	99.92%	39,767	0.08%	0	50,023,247
12	Special resolution to authorise the directors to purchase own shares	47,744,794	99.92%	39,453	0.08%	2,239,000	47,784,247

Enquiries Diaceutics PLC
Stuart Hunt, Head of Investor Relations	Tel: +44 (0)7815 778 536
Cenkos Securities PLC (Nomad & Broker)	Tel: +44(0)20 7397 8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy	Tel: +44 (0)7876 741 001
Paul McManus	Tel: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGZZGMKFLNGGZM